TY - JOUR
T1 - Multicenter performance assessment of Carba NP test
AU - Cunningham, Scott A.
AU - Limbago, Brandi
AU - Traczewski, Maria
AU - Anderson, Karen
AU - Hackel, Meredith
AU - Hindler, Janet
AU - Sahm, Dan
AU - Alyanak, Efe
AU - Lawsin, Adrian
AU - Gulvik, Christopher A.
AU - De Man, Tom J.B.
AU - Mandrekar, Jayawant N.
AU - Schuetz, Audrey N.
AU - Jenkins, Stephen
AU - Humphries, Romney
AU - Palavecino, Elizabeth
AU - Vasoo, Shawn
AU - Patel, Robin
N1 - Funding Information:
R.P. reports grants from BioFire, Check-Points, Curetis, 3M, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company. R.P. is a consultant to Curetis, Roche, Qvella, and Diaxonhit. In addition, R.P. has a patent on Bordetella pertussis/parapertussis PCR with royalties paid by TIB, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. R.P. serves on an Actelion data-monitoring board. R.P. receives travel reimbursement and an editor's stipend from ASM and IDSA and honoraria from the USMLE, Up-to-Date, and the Infectious Diseases Board Review Course.
Publisher Copyright:
© 2017 American Society for Microbiology. All Rights Reserved.
PY - 2017/6
Y1 - 2017/6
N2 - Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance of a test for detection of carbapenemase production, the Carba NP test. The Carba NP test was performed by all laboratories, following the Clinical and Laboratory Standards Institute (CLSI) procedure. Site-versus-site comparisons demonstrated a high level of consistency for the Carba NP assay, with just 3/21 site comparisons yielding a difference in sensitivity (P < 0.05). Previously described limitations with blaOXA-48-like carbapenemases and blaOXA carbapenemases associated with Acinetobacter baumannii were noted. Based on these data, we demonstrate that the Carba NP test, when implemented with the standardized CLSI methodology, provides reproducible results across multiple sites for detection of carbapenemases.
AB - Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance of a test for detection of carbapenemase production, the Carba NP test. The Carba NP test was performed by all laboratories, following the Clinical and Laboratory Standards Institute (CLSI) procedure. Site-versus-site comparisons demonstrated a high level of consistency for the Carba NP assay, with just 3/21 site comparisons yielding a difference in sensitivity (P < 0.05). Previously described limitations with blaOXA-48-like carbapenemases and blaOXA carbapenemases associated with Acinetobacter baumannii were noted. Based on these data, we demonstrate that the Carba NP test, when implemented with the standardized CLSI methodology, provides reproducible results across multiple sites for detection of carbapenemases.
KW - Antimicrobial resistance
KW - Carbapenemase
KW - Gram-negative bacilli
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=85019620148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019620148&partnerID=8YFLogxK
U2 - 10.1128/JCM.00244-17
DO - 10.1128/JCM.00244-17
M3 - Article
C2 - 28404676
AN - SCOPUS:85019620148
SN - 0095-1137
VL - 55
SP - 1954
EP - 1960
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 6
ER -